Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.56 |
| ▸ | RAB9A | P51151 | 9/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21638205 | 1.00 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2MAPTGAA | |
| SCHEMBL13054079 | 1.00 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2MAPTGAA | |
| SCHEMBL23965745 | 0.84 | SMN1; SMN2 (0.60) | NPC1RAB9ASMN1; SMN2MAPTGAA | |
| SCHEMBL13054076 | 0.83 | RAB9A (0.64) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL18344188 | 0.82 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2MAPTGAA | |
| SCHEMBL23965806 | 0.82 | RAB9A (0.52) | NPC1RAB9ASMN1; SMN2MAPTGAA | |
| SCHEMBL21638195 | 0.81 | SMN1; SMN2 (0.56) | NPC1RAB9ASMN1; SMN2MAPTGAA | |
| SCHEMBL21638197 | 0.81 | SMN1; SMN2 (0.56) | NPC1RAB9ASMN1; SMN2MAPTGAA | |
| SCHEMBL21638268 | 0.81 | SMN1; SMN2 (0.56) | NPC1RAB9ASMN1; SMN2MAPTGAA | |
| SCHEMBL21588478 | 0.79 | NPC1 (0.72) | NPC1RAB9ASMN1; SMN2MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3604301-A1 | 4-PYRIDONE COMPOUND OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION AND FORMULATION INCLUDING SAME | FUJIFILM Corporation (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-7838543-B2 | Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles | ELI LILLY AND COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-07-02 | — | — | US | disclosed |
| EP-1828177-B1 | NOVEL MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1828177-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006066173-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | NPC1 689/4885RAB9A 1154/4885SMN1; SMN2 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.